CJ-13610 is an orally bioavailable inhibitor of 5-lipoxygenase (5-LO) . CJ-13610 inhibits the biosynthesis of leukotriene B4 and regulates the IL-6 mRNA expression in macrophages. It is efficacious in preclinical models of pain. References: von Knethen A, Sha LK, Kuchler L, Heeg AK, Fuhrmann D, Heide H, Wittig I, Maier TJ, Steinhilber D, Brüne B. 5-Lipoxygenase contributes to PPARγ activation in macrophages in response to apoptotic cells. Cell Signal. 2013 Dec;25(12):2762-8. doi: 10.1016/j.cellsig.2013.08.045. PubMed PMID: 24036216.

纯度：≥98%

CAS：179420-17-8